Andrea Hörster

Title: Andrea Hörster: Innovator in Recombinant Blood Clotting Factors

Introduction

Andrea Hörster is a notable inventor based in Ebersberg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of recombinant blood clotting factors. His work has the potential to improve treatments for individuals suffering from hemophilia.

Latest Patents

Andrea Hörster holds a patent for an improved method for the production of recombinant human blood clotting factors, specifically factor VIII and factor IX. The patent describes the use of an immortalized human cell line that stably expresses viral transcription activator proteins. This cell line carries a vector with a promoter that is functionally linked to a DNA sequence coding for a blood coagulating factor. Importantly, the promoter is not a viral promoter stimulated by the viral transcription activator proteins. The invention also includes factor VIII muteins suitable for production, pharmaceutical compositions containing these muteins, and their use in preparing medicaments for treating hemophilia. He has 1 patent related to this innovative work.

Career Highlights

Andrea Hörster is currently associated with Octagene GmbH, where he continues to advance research in biotechnology. His expertise in recombinant technologies has positioned him as a key player in the development of therapeutic solutions for blood coagulation disorders.

Collaborations

Andrea collaborates with talented professionals in his field, including Charlotte Hauser and Carola Schröder. Their combined efforts contribute to the innovative research and development at Octagene GmbH.

Conclusion

Andrea Hörster's contributions to the field of recombinant blood clotting factors exemplify the impact of innovation in biotechnology. His work not only advances scientific understanding but also holds promise for improving the quality of life for those affected by hemophilia.